131results about How to "Reduce non-specific binding" patented technology

The invention provides a kit for detecting a trypanosoma cruzi antibody and a preparation method of the kit. The kit comprises a component A and a component B, wherein the component A is a chagas antigen which is marked by a tracking marker or coated with a magnetic ball; the component B is a chagas second antibody which is coated with the magnetic ball or marked by the tracking marker; and any one of the component A and the component B is marked by the tracking marker and the other one is coated with the magnetic ball. The invention further provides a method for detecting the chagas antibody. By utilizing the kit provided by the invention, the concentration of chagas in a sample can be accurately and flexibly determined. On the basis, a pre-treatment solution is used for carrying out pre-treatment optimization so that the background interference can be reduced and the detection flexibility is improved. Meanwhile, detection of the full-automatic chemiluminiscence method can be realized with the help of a chemiluminiscence immunoassay analyzer, so that the operation time is shortened and manual operation errors are reduced.

The invention discloses a detection kit for glycocholic acid for eliminating chyle interference. The detection kit comprises a reagent R1, a reagent R2 and a calibrator. The reagent R1 contains buffer solution a, chyle elimination agent, stabilizer a, surfactant a, reaction promoter a and preservative a; the reagent R2 contains buffer solution b, latex particles of antihuman glycocholic acid monoclonal antibody, stabilizer b, surfactant b, preservative b and reaction promoter b; the calibrator contains buffer solution c, glycocholic acid standard, stabilizer c, surfactant c, reaction promoter c and preservative c. The detection kit is short in detection time, strong in anti-interference capacity, good in stability and repeatability and high in accuracy and detection sensitivity.

The invention provides a cystatin C detection kit and a preparation method thereof. The kit comprises a reagent R1, a reagent R2 and a cystatin C calibration product, wherein the reagent R1 comprisesa preservative, a surfactant, an emulsifier and a buffer solution; the reagent R2 comprises a cystatin C antibody, polystyrene latex microspheres, a latex microsphere activating agent, a sealing agent, an emulsifier, a preservative, a surfactant and a buffer solution. The cystatin C antibody is slowly dropwise added to an activated polystyrene latex microsphere solution, a polystyrene latex microsphere suspension coupled with the cystatin C antibody is obtained after a stirring reaction, sealing is performed, the antibody and latex microspheres are coupled together in a chemical crosslinking manner, and centrifugation, cleaning and ultrasonic resuspension processes in conventional methods are omitted. The production process is simplified, and the kit has the advantages of low blank absorbency, high sensitivity and precision and large linear range.

The invention provides a binding solution, kit and method for purifying nucleic acid by magnetic bead method as well as application. The binding solution comprises a citrate buffer solution, EDTA, sodium acetate, lithium chloride and isopropyl alcohol but does not comprise guanidine salt. The binding solution contains no guanidine salt, can coexist with magnetic beads for a long time and can fullypromote precipitation of nucleic acid and binding with magnetic beads, the low isopropyl alcohol content contributes to increase of the nucleic acid purity, and nonspecific binding of impurities withmagnetic beads is reduced.

This invention discloses one protein chip, which comprises more than two kinds of micro ball fixed with different anti-gastritis label first antibody. This invention also discloses one method for test of the label. This invention also discloses one test agent case with protein chip. This invention protein chip has first antibody volume match design for accurate test.

Belonging to the technical field of immunodetection and analysis, the invention specifically provides a myoglobin enzymatic chemiluminescence immunodetection method. The method includes the steps of: forming a solid phase-antibody-antigen-enzyme-labeled secondary antibody immune sandwich composite and detecting the immune sandwich composite by means of chemiluminescence. The invention also provides a myoglobin enzymatic chemiluminescence immunodetection kit. The detection method and the detection kit provided in the invention are suitable for detection and analysis of myoglobin, and have the advantages of large detection range, and high sensitivity and specificity.

The invention discloses a kit for detecting C-reactive protein through fluorescent immunochromatography. In the kit, a mouse anti-human CRP (C-reactive protein) monoclonal antibody with a fluorescent label and a rabbit IgG (immunoglobulin G) with a fluorescent label are made by subjecting the mouse anti-human CRP monoclonal antibody and the rabbit IgG to fluorescein labeling; in labeling the mouse anti-human CRP monoclonal antibody and the rabbit IgG with fluorescein, the mouse anti-human CRP monoclonal antibody and the rabbit IgG are added into activated fluorescein storage liquid; the concentration of fluorescein in the fluorescein storage liquid is 5-10mg/mL. The kit is high in sensitivity and good in detection stability, enables reduction in nonspecific binding, has a wider linear range, takes only 3 minutes for detection and enables great improvement in diagnostic efficiency.

The invention discloses uPAR (urokinase-type plasminogen activator receptor) targeted peptides with the amino acid sequence indicated in SEQ ID NO. 1. The uPAR targeted peptides is linear peptides formed by 13 amino acids, the peptides are easy to synthesize and can form a stable conformation and be combined with uPARs with specific target. The invention discloses a uPAR targeted probe comprisinga single unit and the above uPAR targeted peptides. The uPAR targeted probe is subjected to specific identification of the peptides and is combined with the uPARs, signals for detection of imaging equipment are transmitted through the signal unit, living visual detection of the uPARs is achieved, and distribution and number of the uPARs are displayed visually and are used for disease detection foruPAR expression abnormalities. The invention further discloses a living molecular imaging method. The uPAR targeted probe is utilized, and the living molecular imaging method has the advantages of being safe, non-invasive, dynamic, visual and the like and is suitable for direct detection of human body.

The invention provides a gold deposition detection method for a gene chip. The method is characterized by comprising the steps of carrying out sample application on an existing DNA sequence to a micro array to prepare the gene chip, previously decorating a biological macromolecule at the 5' end of nucleic acid to be detected, marking the other biological macromolecule matched with a decorative molecule on the nucleic acid to be detected on nanogold to establish a nanogold composite probe, then mixing the decorated nucleic acid to be detected, the marked nanogold composite probe and the gene chip, incubating, washing the unreacted nanogold composite proble and adding hydrogen peroxide gold to enhance reaction liquid observation. The gold deposition detection method for the gene chip has the advantages of being high in flexible, convenient to detect, simple to operate, short in consumed time, low in cost, visual in detection and low in relying degree on detecting and signal reading equipment.

The present invention relates to surface-modified substrates that demonstrate reduced non-specific adsorption of biological agents. The substrates are silicon or carbon substrates having ethylene glycol oligomers covalently bound to at least one substrate surface. The substrates may be used in sensor devices, such as biochips, and in implantable medical devices in order to reduce the non-specific binding of biological agents.

Methods and compositions are disclosed for reducing non-specific binding in a binding assay for the determination of an analyte in a sample wherein one of the reagents for conducting the binding assay is an antibody reagent. The methods comprise treating the antibody reagent at a pH of about 2.0 to about 3.5. The method may further comprise treating the antibody reagent with a reducing agent in an amount sufficient to reduce non-specific binding of the antibody reagent. In some embodiments the reducing agent may be a thiol-containing reducing agent or a combination of two or more thiol-containing reducing agents.

The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.

A chip for protein detection, a method for manufacturing the same, and a method for detecting protein by using the chip are provided in the present invention. The chip for protein detection of the present invention comprises: a substrate; a covalent modification layer disposed on the substrate; a fluorinated layer disposed on the covalent modification layer, wherein the fluorinated layer comprises fluorinated functional groups and bio-molecular binding groups; and antibody-binding molecules connecting to the bio-molecular binding groups.

The invention provides a kit for quantitatively detecting a heart-type fatty acid binding protein. The kit comprises a heart-type fatty acid binding protein calibrator, a magnetic particle coupled with an anti-biotin antibody, an acridine derivative-labeled heart-type fatty acid binding protein monoclonal antibody, a biotin-labeled heart-type fatty acid binding protein monoclonal antibody, a chemiluminescent substrate and a quality control substance. A preparation method of the kit comprises the following steps: preparing the calibrator from a pure heart-type fatty acid binding protein raw material; preparing the acridine derivative-labeled antibody; preparing a biotinylated antibody; coupling a magnetic particle with the anti-biotin antibody; sub-packaging the calibrator, a marker mixturesolution and the chemiluminescent substrate; and performing assembling to obtain the finished product. The kit has the advantages of high sensitivity, good specificity, high accuracy of a quantitative detection result, low use cost, and easiness in promotion and application.

The invention discloses a combined chemiluminescent detection kit and a detection method. The combined chemiluminescent detection kit comprises a specific conjugate of a to-be-detected substance, a microparticle, a solid-phase film, a chemiluminescent reagent, a centrifugal device and a luminescent detector, wherein the chemiluminescent reagent comprises at least one selected from a group consisting of a chemiluminescent enzyme, a chemiluminescent substance, a chemiluminescent enzyme reaction substrate and a starting luminescent reagent; the microparticle is a particle capable of specifically binding to a protein and/or the chemiluminescent reagent in a direct binding and/or chemically crosslinking way and maintaining stable; the solid-phase membrane is a membranous substance having the characteristic of non-specific binding to a protein; the centrifugal device is a structure capable of centrifugally driving chromatographic flowing of a liquid phase on the solid-phase membrane; and the specific conjugate of the to-be-detected substance is at least one selected from a group consisting of antigen, antibody, avidin, biotin and analogue thereof with specific binding ability. The combined chemiluminescent detection kit and the detection method in the invention have the characteristics of high sensitivity and short detection time, and have good application prospects.

A reagent system for printing, assaying, and processing nucleic acid microarrays is provided. The system comprises: a printing kit, which includes a nucleic acid spotting solution; and a hybridization kit, which includes a nucleic acid pre-hybridization solution, a nucleic acid hybridization solution, and first, second, and third wash reagents, wherein the respective constituent components of the printing and hybridization kits are stable and retain functional performance, when stored together at a temperature between about 10° C. to about 50° C. A background reducing agent or solution is also included. The present reagent solutions are optimized for use with glass substrates having preferably an amine-coating, such as GAPS.

The invention relates to a DNA pulldown method and a kit. The method includes the following steps of pretreating magnetic beads, wherein the magnetic beads marked by BSA(bovine serum albumin) and oligonucleotide random primer closed streptavidin are used; preparing a probe-magnetic bead compound; extracting and pretreating cell nucleus protein, wherein deoxyribonuclease is added into an extracting nucleoprotein sample for incubation, the magnetic beads are added for incubation and then removed, and supernatant is collected; carrying out pulldown; collecting the protein sample. The DNA pulldown method has the following advantages that BSA and an oligonucleotide random primer are used for closing the magnetic beads in advance, and nonspecific binding between the magnetic beads, protein and genomic DNA is reduced. Nuclease contamination is prevented through systemic nuclease protection, stability and reliability of experiments are improved, repeatability is high, and the experiment process is simplified.

The invention discloses a kit for detecting short-chain fatty acid. The kit comprises a kit body, an elisa plate arranged in the kit body, a short-chain fatty acid standard substance gradient solution, a sample diluent, an alkaline phosphatase labeled antibody for detecting an anti-short-chain fatty acid conjugate, a 20* concentrated washing solution, a color developing agent, a stop solution, a plate sealing film, a sealing bag and an instruction book, wherein the elisa plate is a transparent polystyrene 96 or 48-hole elisa plate, and each hole of the elisa plate is coated with an anti-short-chain fatty acid monoclonal antibody Mab1 with the concentration of 5mu g/mL. The short-chain fatty acid standard substance gradient solution has six concentrations, separately 20 ng/mL, 10 ng/mL, 5 ng/mL, 2.5 ng/mL, 1.25 ng/mL and 0 ng/mL. The detection kit provided by the invention provides an enzyme-labeled secondary antibody labeled by alkaline phosphatase (ALP), so that the stability and sensitivity of the kit are remarkably improved.

The invention relates to a test strip capable of quantificationally detecting content of c-reactive protein in peripheral blood. The test strip comprises a sample cushion, a quantum cushion, a nitrocellulose membrane, water absorbing paper and a lining plate, the quantum cushion wraps c-reactive protein antibodies marked by carbon quantum dots, and a detecting line and a quality control line are successively arranged on the nitrocellulose membrane from the sample cushion side to the water absorbing paper side; the detecting line wraps c-reactive protein recognizing monoclonal antibodies, and the quality control line wraps goat anti mouse IgG. The test strip is simple in structure and can quickly and accurately detect CRP in the peripheral blood quantificationally, the detection of the teststrip is high in sensitivity and stability and good in specificity, the detecting time is shorter than 15 min, and the diagnostic efficiency and the work efficiency of detecting operators can be greatly improved.